Journal Home
Search for

Volume 7, Issue 2, Pages 239-245 (February 2009)


View previous. 28 of 37 View next.

A Retrospective Single-Center Review of Primary Sclerosing Cholangitis in Children

Tamir Miloh, Ronen Arnon, Benjamin Shneider, Frederick Suchy, Nanda KerkarCorresponding Author Informationemail address

published online 03 November 2008.

Background & Aims

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and progressive bile duct fibrosis. There are limited data on pediatric PSC.

Methods

We performed a retrospective chart review of 47 pediatric patients with PSC.

Results

The mean age at diagnosis was 11 ± 4.9 years. Symptoms occurred before presentation in 81% of patients; inflammatory bowel disease was found in 59% and autoimmune hepatitis (overlap syndrome) in 25% of patients. Magnetic resonance cholangiography revealed both extrahepatic and intrahepatic, isolated intrahepatic, isolated extrahepatic, and no biliary involvement (small-duct PSC) in 40%, 14%, 10%, and 36%, respectively. Advanced fibrosis (stage >II) was present in 65%. Colonoscopy revealed pancolitis, rectal sparing, and normal findings in 24%, 24%, and 18%, respectively. All patients were treated with ursodeoxycholic acid (UDCA); 9 with overlap syndrome also received immunosuppressants. Fifteen patients without overlap syndrome had positive autoimmune markers and responded to UDCA monotherapy. Liver transplantation was performed in 9 patients (3 with overlap syndrome and 2 with small-duct PSC) at a median time of 7 years after diagnosis. The 10-year posttransplant survival rate was 89%.

Conclusions

In one of the largest single-center studies of children with PSC, we found that most children with PSC had inflammatory bowel disease or autoimmune overlap and advanced fibrosis at diagnosis. Levels of alanine aminotransferase and γ-glutamyl transferase were highest in patients with overlap syndrome and lowest in those with small-duct PSC. Levels of serum liver enzymes normalized after therapy with UDCA, including patients with positive autoimmune markers without histologic features of autoimmune hepatitis.

 Department of Pediatrics, Department of Surgery, and Recanati/Miller Transplant Institute, Mount Sinai Hospital, New York, New York

 Department of Pediatric Gastroenterology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Corresponding Author InformationAddress requests for reprints to: Nanda Kerkar, MD, Associate Professor of Pediatrics and Surgery, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1104, New York, New York 10029. fax: (212) 659-8066

 The authors disclose no conflicts.

PII: S1542-3565(08)01050-1

doi:10.1016/j.cgh.2008.10.019


View previous. 28 of 37 View next.